Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C28H27NO4S · HCl
CAS Number:
Molecular Weight:
510.04
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
agency
USP
API family
raloxifene
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
Cl[H].Oc1ccc(cc1)-c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4
InChI
1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H
InChI key
BKXVVCILCIUCLG-UHFFFAOYSA-N
Gene Information
human ... ESR2(2100)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Raloxifene hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Raloxifene Hydrochloride Tablets
Biochem/physiol Actions
Raloxifene is a selective estrogen receptor modulator (SERM); acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. May have efficacy against estrogen-sensitive cancers.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Raloxifene hydrochloride
signalword
Warning
hcodes
Hazard Classifications
Carc. 2 - Repr. 2
Storage Class
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tuan Hiep Tran et al.
Journal of nanoscience and nanotechnology, 14(7), 4820-4831 (2014-04-25)
The main aim of this study was to improve the oral bioavailability of raloxifene (RXF), a selective estrogen receptor modulator, by incorporation into solid lipid nanoparticles (SLN). RXF-loaded SLN was prepared by homogenization-sonication technique and characterized through physicochemical, pharmacokinetic, and
[Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
Hiroyuki Kobayashi et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 125(1), 37-48 (2005-03-02)
K R Snyder et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 57(18), 1669-1675 (2000-09-28)
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and therapeutic role of raloxifene hydrochloride are reviewed. Raloxifene is a selective estrogen-receptor modulator (SERM) that has been approved for use in the prevention and treatment of osteoporosis in postmenopausal women. A SERM
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 1598201-200MG | 04061833854358 |
